Nondetectable Prostate Carcinoma (pT0) after Radical Prostatectomy: A Narrative Review.


Journal

Current oncology (Toronto, Ont.)
ISSN: 1718-7729
Titre abrégé: Curr Oncol
Pays: Switzerland
ID NLM: 9502503

Informations de publication

Date de publication:
23 02 2022
Historique:
received: 30 01 2022
revised: 15 02 2022
accepted: 16 02 2022
entrez: 24 3 2022
pubmed: 25 3 2022
medline: 15 4 2022
Statut: epublish

Résumé

(1) Background: Following radical prostatectomy (RP), the absence of a demonstrable tumor on the specimen of a previously histologically proven malignancy is known as the pT0 stage. The aim of our present study is to perform a narrative review of current literature in order to determine the frequency and oncological outcomes in patients with pT0 disease. (2) Methods: A narrative review of all available literature was performed. (3) Results: The incidence of pT0 ranges between 0.07% and 1.3%. Predictors of the pT0 stage are only a single biopsy core with low-grade cancer, a cancer length not exceeding 2 mm and a high prostate volume. Biochemical recurrence ranges between 0 and 11%. (4) Conclusions: The absence of malignancy in the RP specimen despite a previous positive biopsy is a rare and unpredictable finding. Although the prognosis is considered to be excellent in most of the cases, a continued close follow-up is warranted.

Identifiants

pubmed: 35323311
pii: curroncol29030111
doi: 10.3390/curroncol29030111
pmc: PMC8946857
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

1309-1315

Références

J Surg Oncol. 2010 Sep 15;102(4):331-3
pubmed: 20589707
BJU Int. 2016 Sep;118(3):379-83
pubmed: 26305996
Curr Urol. 2013 Aug;7(1):14-8
pubmed: 24917750
Int J Urol. 2011 Feb;18(2):148-53
pubmed: 21198944
Urology. 2003 Sep;62(3):476-80
pubmed: 12946750
Urology. 2004 Oct;64(4):733-7
pubmed: 15491711
Eur Urol. 2004 Jan;45(1):42-5
pubmed: 14667514
Eur Urol. 2000 Dec;38(6):714-20
pubmed: 11111189
Am J Surg Pathol. 2005 Apr;29(4):467-73
pubmed: 15767799
Eur Urol. 2006 Dec;50(6):1248-52; discussion 1253
pubmed: 16828964
Korean J Urol. 2010 Jun;51(6):386-90
pubmed: 20577604
Urology. 1999 Mar;53(3):523-9
pubmed: 10096378
Urol Oncol. 2019 Oct;37(10):696-701
pubmed: 31129038
BJU Int. 2004 Jul;94(1):57-8
pubmed: 15217431
Eur Urol. 2004 Jan;45(1):36-41
pubmed: 14667513
Am J Surg Pathol. 1995 Sep;19(9):1002-9
pubmed: 7661273
Cancer. 1994 Mar 1;73(5):1472-7
pubmed: 8111715
J Urol. 2010 Mar;183(3):958-62
pubmed: 20083270
Eur Urol. 1993;24(4):461-5
pubmed: 8287886
Arch Pathol Lab Med. 2006 Jun;130(6):811-6
pubmed: 16740032
PLoS One. 2018 Dec 28;13(12):e0210037
pubmed: 30592769
Am J Surg Pathol. 1997 Feb;21(2):174-8
pubmed: 9042283

Auteurs

Nikolaos Kalampokis (N)

Department of Urology, G. Hatzikosta General Hospital, 45001 Ioannina, Greece.

Nikolaos Grivas (N)

Department of Urology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, The Netherlands.
Department of Urology, Lefkos Stavros Hospital, 11528 Athens, Greece.

Markos Karavitakis (M)

Department of Urology, Lefkos Stavros Hospital, 11528 Athens, Greece.
Department of Urology, University General Hospital of Heraklion, University of Crete, Medical School, 14122 Heraklion, Greece.

Ioannis Leotsakos (I)

Department of Urology, Lefkos Stavros Hospital, 11528 Athens, Greece.
Department of Urology, Medical School, National & Kapodistrian University of Athens, 14122 Athens, Greece.

Ioannis Katafigiotis (I)

Department of Urology, Lefkos Stavros Hospital, 11528 Athens, Greece.
Department of Urology, Medical School, National & Kapodistrian University of Athens, 14122 Athens, Greece.

Marcio Covas Moschovas (MC)

Department of Urology, Advent Health Global Robotics Institute, Celebration, FL 34747, USA.

Henk van der Poel (H)

Department of Urology, The Netherlands Cancer Institute-Antoni van Leeuwenhoek Hospital, 1066 CX Amsterdam, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH